Literature DB >> 17122023

Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.

Toshihiro Nishizawa1, Hidekazu Suzuki, Ayako Umezawa, Hiroe Muraoka, Eisuke Iwasaki, Tatsuhiro Masaoka, Intetsu Kobayashi, Toshifumi Hibi.   

Abstract

Helicobacter pylori strains with reduced susceptibility to fluoroquinolones have a mutation at either codon 87 Asn or 91 Asp of the gyrA gene. A rapid test based on an allele-specific PCR (AS-PCR) was designed to detect the gyrA mutations. Clinical H. pylori isolates were obtained from the stomachs of 51 patients with H. pylori infections who showed treatment failure. The MICs of gatifloxacin (GAT) were determined by the agar dilution method. Identical genotyping results were obtained with AS-PCR and conventional PCR. The gyrA mutations of H. pylori causing reduced susceptibility to fluoroquinolones could be detected successfully by this method. A significant association was observed between the presence of mutations, as detected by AS-PCR, and the resistance of the strains to GAT. Moreover, genotyping by AS-PCR took less than 3 to 4 h. The AS-PCR method for the detection of gyrA mutations in H. pylori is useful for easy identification of fluoroquinolone-resistant strains of H. pylori.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17122023      PMCID: PMC1829027          DOI: 10.1128/JCM.01997-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR.

Authors:  M Hersberger; J Marti-Jaun; K Rentsch; E Hänseler
Journal:  Clin Chem       Date:  2000-08       Impact factor: 8.327

2.  Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.

Authors:  Ala I Sharara; Hani F Chaar; Elie Aoun; Heitham Abdul-Baki; George F Araj; Souha S Kanj
Journal:  Helicobacter       Date:  2006-08       Impact factor: 5.753

Review 3.  Genetic variability within Helicobacter pylori.

Authors:  S Suerbaum
Journal:  Int J Med Microbiol       Date:  2000-05       Impact factor: 3.473

4.  High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5' nuclease chain reaction assay.

Authors:  M Hiratsuka; Y Agatsuma; F Omori; K Narahara; T Inoue; Y Kishikawa; M Mizugaki
Journal:  Biol Pharm Bull       Date:  2000-10       Impact factor: 2.233

5.  PCR-based diagnosis of Helicobacter pylori infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples.

Authors:  S A Chisholm; R J Owen; E L Teare; S Saverymuttu
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.

Authors:  T Masaoka; H K SuzukiKurabayashi; A G Kamiya; H Ishii
Journal:  Aliment Pharmacol Ther       Date:  2004-07       Impact factor: 8.171

7.  In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children.

Authors:  Shigeru Fujimura; Seiichi Kato; Kazuie Iinuma; Akira Watanabe
Journal:  J Med Microbiol       Date:  2004-10       Impact factor: 2.472

8.  Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach.

Authors:  Erik Glocker; Manfred Kist
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

9.  Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.

Authors:  Jacques Tankovic; Christine Lascols; Quentin Sculo; Jean-Claude Petit; Claude-James Soussy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  Characterization of cytochrome P450 2D6 alleles using the Invader system.

Authors:  Matt Nevilie; Rebecca Selzer; Brian Aizenstein; Megan Maguire; Kirk Hogan; Robert Walton; Ken Welsh; Bruce Neri; Monika de Arruda
Journal:  Biotechniques       Date:  2002-06       Impact factor: 1.993

View more
  15 in total

1.  Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.

Authors:  Jyh-Ming Liou; Chi-Yang Chang; Wang-Huei Sheng; Yu-Chi Wang; Mei-Jyh Chen; Yi-Chia Lee; Hsu-Wei Hung; Hung Chian; San-Chun Chang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

2.  Point Mutations at gyrA and gyrB Genes of Levofloxacin-Resistant Helicobacter pylori Isolates in the Esophageal Mucosa from a Venezuelan Population.

Authors:  Mariela López-Gasca; Jessy Peña; María-Alexandra García-Amado; Fabián Michelangeli; Monica Contreras
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

3.  Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Hitoshi Tsugawa; Hiroe Muraoka; Juntaro Matsuzaki; Kenro Hirata; Fumiaki Ikeda; Masahiko Takahashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

Review 4.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

5.  Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Takama Maekawa; Naohiko Harada; Tatsuya Toyokawa; Toshio Kuwai; Masanori Ohara; Takahiro Suzuki; Masahiro Kawanishi; Kenji Noguchi; Toshiyuki Yoshio; Shinji Katsushima; Hideo Tsuruta; Eiji Masuda; Munehiro Tanaka; Shunsuke Katayama; Norio Kawamura; Yuko Nishizawa; Toshifumi Hibi; Masahiko Takahashi
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

6.  Helicobacter pylori resistance to rifabutin in the last 7 years.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Juntaro Matsuzaki; Hiroe Muraoka; Hitoshi Tsugawa; Kenro Hirata; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

Review 7.  Helicobacter pylori: present status and future prospects in Japan.

Authors:  Hidekazu Suzuki; Toshifumi Hibi; Barry James Marshall
Journal:  J Gastroenterol       Date:  2007-02-16       Impact factor: 7.527

8.  Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori.

Authors:  Emmanuelle Cambau; Vera Allerheiligen; Céline Coulon; Céline Corbel; Christine Lascols; Lionel Deforges; Claude-James Soussy; Jean-Charles Delchier; Francis Megraud
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

Review 9.  Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Authors:  Evariste Tshibangu-Kabamba; Yoshio Yamaoka
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-17       Impact factor: 46.802

10.  Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Toshifumi Hibi
Journal:  J Clin Biochem Nutr       Date:  2009-02-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.